Tysabri Reimbursement Is Not Restricted By One-Year Data, Biogen Idec Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Biogen Idec/Elan have held discussions with 700 payors in an effort to minimize reimbursement barriers for the recently approved multiple sclerosis therapy; another 1,000 are planned. The companies expect to release two-year data from the pivotal trials next year.
You may also be interested in...
Biogen Idec/Elan's Tysabri Priced At Premium To Serono/Pfizer's Rebif
With a wholesale acquisition cost of $1,808, Tysabri will sell for at least a 20% premium to Rebif. Pricing for the MS therapy reflects the expectation of future indications in Crohn's and rheumatoid arthritis.
Elan/Biogen Idec's Tysabri, Formerly Antegren, Approved For MS Based On One-Year Data
Monoclonal antibody's label includes studies as monotherapy and as add-on in patients previously treated with Avonex. Two-year results are expected in the first half of 2005.
U.S. Patents Could Limit President's AIDS Drug Assistance Plan, GAO Says
The U.S. Global AIDS Coordinator's Office suggests it will use its authority to purchase an FDA-approved generic antiretroviral product for which permission could not be obtained from the patent holder. FDA grants tentative approval to a South African firm for a generic co-packaged version of Combivir and Viramune.